Dynavax's Adjuvant-Based Bivalent COVID-19 Vaccine Candidate Shows Encouraging Preclinical Action

 

• Clover Biopharmaceuticals Ltd announced new promising data from a preclinical study on its bivalent vaccine candidate, which combines the trimeric spike antigens from the original SARS-CoV-2 strain and the omicron variant. 
• Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus. It includes Dynavax Technologies Corporation's 
  DVAX-5.25%+ Free Alerts
   CpG 1018 advanced adjuvant and aluminum hydroxide. 
• In a preclinical study, the bivalent vaccine candidate elicited broad neutralization against all Variants of Concern (VoC), including omicron, in primary vaccination and booster settings. 
• Notably, compared to the monovalent omicron variant vaccine (SCB-2022B) alone, the bivalent COVID-19 vaccine demonstrated higher neutralization levels against most of the variants tested and comparable levels against omicron.
• Clover expects to initiate a Phase 1 trial in Q2 evaluating SCB-2020S (a prototype and beta-variant chimeric vaccine candidate) to demonstrate proof-of-concept for variant strain change utilizing the Trimer-Tag platform.

https://www.benzinga.com/general/biotech/22/05/27026845/dynavaxs-adjuvant-based-bivalent-covid-19-vaccine-candidate-shows-encouraging-preclinical-action